Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EXAS 
EXACT Sciences Corporation (EXAS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: EXAS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $64.01
1 Year Target Price $64.01
| 17 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -26.54% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.92B USD | Price to earnings Ratio - | 1Y Target Price 64.01 |
Price to earnings Ratio - | 1Y Target Price 64.01 | ||
Volume (30-day avg) 26 | Beta 1.05 | 52 Weeks Range 38.81 - 72.83 | Updated Date 09/17/2025 |
52 Weeks Range 38.81 - 72.83 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -34.19% | Operating Margin (TTM) 0.34% |
Management Effectiveness
Return on Assets (TTM) -1.39% | Return on Equity (TTM) -35.51% |
Valuation
Trailing PE - | Forward PE 71.94 | Enterprise Value 11685575683 | Price to Sales(TTM) 3.37 |
Enterprise Value 11685575683 | Price to Sales(TTM) 3.37 | ||
Enterprise Value to Revenue 3.97 | Enterprise Value to EBITDA 215.11 | Shares Outstanding 189319110 | Shares Floating 187461890 |
Shares Outstanding 189319110 | Shares Floating 187461890 | ||
Percent Insiders 0.91 | Percent Institutions 95.61 |
Upturn AI SWOT
EXACT Sciences Corporation
Company Overview
History and Background
EXACT Sciences Corporation was founded in 1995. Initially focused on genetic research, it evolved to specialize in early cancer detection. The company's Cologuard test marked a significant milestone, revolutionizing non-invasive colon cancer screening.
Core Business Areas
- Colorectal Cancer Screening: This segment focuses on the development, manufacturing, and commercialization of Cologuard, a non-invasive, stool-based DNA screening test for colorectal cancer.
- Precision Oncology: This includes products and services related to cancer diagnostics and monitoring, such as Oncotype DX, which provides genomic intelligence to personalize cancer treatment decisions.
Leadership and Structure
The company's leadership team comprises experienced executives in diagnostics, oncology, and finance. The organizational structure is designed to support both the commercialization of Cologuard and the development of its precision oncology portfolio.
Top Products and Market Share
Key Offerings
- Cologuard: A non-invasive stool DNA screening test for colorectal cancer. Cologuard has a significant share of the at-home colon cancer screening market, estimated to be around 60%. Competitors include traditional colonoscopies, fecal immunochemical tests (FIT), and other stool DNA tests. Revenue from Cologuard accounts for a large portion of Exact Sciences' total revenue.
- Oncotype DX: A suite of genomic tests that analyze tumor samples to predict the likelihood of cancer recurrence and response to therapy. It assists physicians in making personalized treatment decisions for patients with breast, colon, and prostate cancer. Competitors include other genomic testing companies such as Myriad Genetics.
Market Dynamics
Industry Overview
The cancer diagnostics market is experiencing substantial growth, driven by increasing cancer incidence, advancements in genomic technologies, and a growing emphasis on early detection and personalized medicine.
Positioning
EXACT Sciences is a leader in non-invasive cancer screening and precision oncology. Its competitive advantages include its established Cologuard brand, its strong relationships with healthcare providers, and its ongoing investment in research and development.
Total Addressable Market (TAM)
The estimated total addressable market is estimated to be in the tens of billions of dollars. Exact Sciences is well-positioned with Cologuard in the colon cancer screening market and Oncotype DX in precision oncology. Their expansion efforts through research and acquisitions aim to capture a larger share of the overall cancer diagnostics market.
Upturn SWOT Analysis
Strengths
- Strong brand recognition for Cologuard
- Established market position in non-invasive colon cancer screening
- Proprietary technology and intellectual property
- Extensive sales and marketing network
- Growing precision oncology portfolio
Weaknesses
- Reliance on Cologuard for a significant portion of revenue
- High marketing and sales expenses
- Potential for reimbursement challenges
- Competition from established diagnostic companies
Opportunities
- Expanding the use of Cologuard to younger age groups
- Developing new cancer screening and diagnostic tests
- Acquiring complementary technologies and businesses
- Partnering with healthcare providers and payers
Threats
- Increased competition from new and existing players
- Changes in reimbursement policies
- Negative publicity regarding the accuracy or effectiveness of Cologuard
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- GHDX
- HOLX
- MYGN
Competitive Landscape
EXACT Sciences has a strong position in the at-home colon cancer screening market with Cologuard. However, it faces competition from established diagnostic companies like Guardant Health, Hologic, and Myriad Genetics in other areas such as liquid biopsy and genomic testing. EXAS' competitive advantage is its brand recognition and marketing prowess for Cologuard.
Major Acquisitions
PreventionGenetics
- Year: 2021
- Acquisition Price (USD millions): 190
- Strategic Rationale: Expanded EXACT Sciences' precision oncology portfolio and capabilities in genetic testing.
Growth Trajectory and Initiatives
Historical Growth: EXACT Sciences has experienced rapid revenue growth in recent years, primarily driven by the adoption of Cologuard.
Future Projections: Analysts project continued revenue growth for EXACT Sciences, fueled by increased Cologuard adoption and the expansion of its precision oncology portfolio. Profitability is expected to improve as the company achieves greater scale.
Recent Initiatives: Recent strategic initiatives include expanding the Cologuard marketing campaign, investing in research and development, and acquiring complementary businesses in the precision oncology space.
Summary
EXACT Sciences has built a strong position in the non-invasive colon cancer screening market with Cologuard, driving significant revenue growth. While profitability remains a challenge, its expansion into precision oncology offers future potential. Increased competition and reimbursement risks need to be carefully managed. The company's continuous innovation and strategic acquisitions are crucial for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10K, 10Q)
- Analyst Reports
- Company Investor Relations
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About EXACT Sciences Corporation
Exchange NASDAQ | Headquaters Madison, WI, United States | ||
IPO Launch date 2001-02-01 | Chairman of the Board & CEO Mr. Kevin T. Conroy J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 6900 | Website https://www.exactsciences.com |
Full time employees 6900 | Website https://www.exactsciences.com | ||
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.